Loading ...
Sorry, an error occurred while loading the content.

900Angiogenesis: Mpls/NCI/other

Expand Messages
  • Janice and Ben Haines
    Sep 23, 1998
    • 0 Attachment
      Greetings,
      Here are various articles on angiogenesis. I couldn't believe THE MAN
      (Folkman) was 15 minutes away from us at the Minneapolis Club, last
      Thursday. I am posting an article for our research from today's Minneapolis
      Star Tribune. After the MPLS article are a few older articles on
      angiogenesis but I find them fascinating. The BUZZ is Folkman is going to
      win the Nobel Prize on October 12th. Mark my words, THE MAN is going to
      win!!! Every where I turn, the momentum is continuing and people are
      excited. Do some of your own research and you will see. I have been
      corresponding with the Web Editor at NCI giving her praise for her work on
      the new web pages you have to check them out:
      http://207.121.187.155/NCI_CANCER_TRIALS/zones/PressInfo/Angio/

      One page thoroughly walks through many of the antiangiogenic drugs in
      trials. Here is an excerpt of what NCI has on their website: (It echos my
      upgraded condition from 'cautiously optimistic.')

      Remember, this is NCI making this statement:

      http://207.121.187.155/NCI_CANCER_TRIALS/zones/PressInfo/Angio/angart.html
      <snip>
      Also, because anti-angiogenic drugs are designed to prevent
      the further growth of tumors, but do not necessarily kill tumors,
      anti-angiogenic therapy may prove useful in combination with
      therapy aimed at tumor cells. Early trials using marimastat and
      another angiogenesis inhibitor, TNP-470, in combination with
      standard cytotoxic drugs have begun.

      For some researchers, however, not even cautious optimism
      seems appropriate. "All the information we have is that the drug
      is working," said Rasmussen. "We have treated 2,500 patients
      and we haven't seen any problems yet. I would be stunned if
      the drug doesn't work."
      ----------------------
      Regards,
      -Ben(KIA)
      p.s. - thanks for the notes today. There were many, however, confused about
      results from Phase I trials of Rituxan. I posted that a YEAR ago, Rituxan
      was has since been approved (November 1997) and can be recommended by any
      oncologist in America, so ask your oncologist and maybe take the PROMISING
      PROTOCOLS post with you to discuss options. I am not sure how Rituxan is
      marketed around the world but rights have been purchased for it under the
      name of MABTHERA and THERAMAB.
      -----8<---8<---

      From (for research purposes):
      http://webserv1.startribune.com/cgi-bin/stOnLine/article?thisSlug=OBS23&date
      =23-Sep-98&word=dawson

      Published Wednesday, September 23, 1998

      The Observatory: A peek into the future of the war on cancer?
      (The subhead, missing from the web but in the paper read:
      "The reports from Judah Folkman's lab and case studies are electrifying the
      medical community")

      Jim Dawson / Star Tribune

      After showing his last slide and making his final point, Dr. Judah Folkman
      stepped back from the lectern at the Minneapolis Club last Thursday night
      and waited for questions from his audience of surgeons.

      A couple of doctors asked for a few more details about his research, but
      most of the hundred or so physicians, many of them cancer specialists, just
      sat quietly at their tables. When he stepped down from the podium, the room
      erupted in loud applause.

      "Do you realize who this is?" a surgeon said to me. "This is the man who is
      going to put us out of business."

      Folkman is the Harvard Medical School professor who won national acclaim
      earlier this year for his discoveries of two experimental cancer drugs,
      which, so far, have wiped out a host of cancer tumors in mice.

      The drugs, angiostatin and endostatin, seem almost too good to be true. The
      tumors die, the mice get better, and life goes on. There don't seem to be
      any side effects, and the mice don't build up a resistance to the drugs. If
      the tumors come back, the scientists give them more drugs, and the cancer
      goes away again.

      In May a controversial New York Times story described Folkman as the man
      who would cure cancer within a couple of years. Nobel laureate James
      Watson, the biochemist who helped discover the structure of DNA, was quoted
      as making that prediction. But he quickly backed away from it a few days
      later, saying he didn't actually say, or at least mean, "cure" cancer.

      Still, stories about Folkman filled newspapers and magazines throughout the
      country. Many urged caution, and quoted Folkman as saying that he hadn't
      found a cure for cancer, except maybe in mice. The promising new drugs
      hadn't been tested in humans, and it was too early to get excited, experts
      said.

      Caution is a good thing, but after listening to Folkman speak to the
      Minneapolis Surgical Society last week, many in the room seemed in awe of
      what they had heard. Although the two newest drugs from Folkman's lab
      haven't been tested in humans, other, less powerful versions have, all
      designed to cut off the blood supply to tumors. The results, as he
      presented them last week, have been remarkable.

      Astounding recoveries

      There was the little girl with the tumor on her face at Children's Hospital
      in Boston, where Folkman practices. Traditional treatment failed, and the
      girl faced traumatic surgery that would disfigure her face. He stepped in
      with an early version of one of his anti-cancer drugs. The tumor went away.
      That was a few years ago. It hasn't come back.

      "Never listen to a physician who talks to you about success on one case,"
      Folkman said after telling her story. "But now we have five, and they've
      all been successful."

      So the night went. There was the woman with cancer of the cervix that had
      spread to her lungs. All the traditional treatments had failed. She started
      taking the first drug that Folkman helped develop, called TNP-470, through
      blood infusion three days a week. The cancer lesions in her lungs stopped
      growing, Folkman said, then they went away. The woman gained 11 pounds.
      More than two years later, he said, she "continues to be tumor free."

      "And if the tumor recurs, she can do it again [take the drug] any time,
      because she doesn't have drug resistance."

      None of these drugs has been tested long enough to win approval from the
      U.S. Food and Drug Administration. And Folkman is the first to issue words
      of caution.

      "Have you cured cancer?" a medical student from the Mayo Clinic asked him.

      "I think this is an improvement, a step in the right direction," he
      replied. The real cure for cancer may come a couple of decades from now,
      when "you have a simple molecular cure."

      He avoids the word "cure." After the New York Times piece ran, his office
      received a thousand phone calls a day from people suffering from cancer.
      More stories will trigger more calls. And there isn't much Folkman can do
      for the callers. The drugs, which are natural proteins, are proving
      difficult to replicate, but pharmaceutical companies are working overtime
      to understand and develop them. Human testing of the latest drugs will
      start in February or March, and if the history of medicine is a guide,
      there will problems to overcome.

      'A paradigm shift'

      When pressed, Folkman acknowledges that his work may be more than just a
      step in the fight against cancer. It might be a "paradigm shift," he said
      -- a fundamental change in the way we approach the disease.

      He foresees a time when there will be "cancer without disease." In other
      words, you have cancer, but it is controlled, and you aren't sick.

      When today's children are adults, will they fear cancer the same way their
      parents do? Folkman answered with a bit of history. Before antibiotics,
      people were terrified of pneumonia because it killed so many, he said. "Now
      we treat it on an outpatient basis. In the future we'll treat cancer on an
      outpatient basis."

      The surgeons who listened to Folkman seemed to think the future isn't far
      away.

      -- Jim Dawson is a Star Tribune science writer.

      © Copyright 1998 Star Tribune. All rights reserved.

      ----8<----8<-----
      (Dated but I use these for quotes and reference)
      http://www.usnews.com/usnews/issue/9angio.htm 12/9/1996

      They called his theory ridiculous

      Now it's revolutionizing cancer treatment

      Every few years, Dr. Judah Folkman delivers a lecture to Harvard medical
      students on the difference between obstinacy and persistence. "It's a fine
      line," he says. "If your idea succeeds, everybody says you're persistent.
      If it doesn't succeed, you're obstinate." Folkman should know. He has
      endured the ridicule of critics, who have called him a clown--and worse.
      And he once watched an auditorium empty when he stood up to give a
      scientific talk. But the surgeon and cell biologist at Children's Hospital
      in Boston has never wavered from the deceptively simple-sounding theory he
      first outlined 25 years ago, a theory that is having profound implications
      for the treatment of cancer: Tumors need a blood supply in order to grow.

      As it turns out, Folkman is likely to go down in history as persistent, not
      merely pigheaded. Over the past decade, the scientist not only has proved
      his basic premise but in the process has opened a portal on some of
      cancer's most perplexing secrets. Researchers now understand, for example,
      that tumors use tricks to induce nearby blood vessels into providing that
      blood supply by sprouting tiny branches called capillaries. The tumor then
      uses these capillaries as highways to spread--or metastasize--to far-flung
      sites in the body.

      Now, Folkman's lab has produced the most spectacular finding yet: two
      substances that can cut off a tumor's blood supply, stopping cancer in its
      tracks. If these drugs work in people as well as they do in mice, they
      could reverse the deadly odds cancer patients face once their tumors have
      spread.

      Folkman's idea rests on the observation that once a tumor grows beyond a
      few hundred thousand cells--a mass no bigger than a BB--the cells at its
      center don't get enough blood. To nourish them, the tumor must send out
      chemical signals that induce capillaries to grow--a process known as
      angiogenesis, from the Greek angos, for vessel.

      Finding the switch. Folkman's theory led him to search for biochemical
      messengers that tumors use to turn on blood vessel cells. In 1983, his lab
      found the first of these angiogenesis growth factors. Two years later, his
      team fished out another substance: This one turned off blood vessel cells,
      slowing the growth of capillaries and--Folkman hoped--some tumors as well.

      The discoveries turned his critics into competitors. Today, over two dozen
      pharmaceutical firms are racing to complete clinical trials of nine
      so-called angiogenesis inhibitors in human patients with a variety of
      tumors, including cancer of the colon and breast. The drugs are not strong
      enough to battle cancer alone. Instead, they provide a one-two punch when
      combined with standard radiation and chemotherapy. The angiogenesis
      inhibitors starve the tumor by shrinking its blood vessels, while the
      standard treatment attacks the cancer itself.

      Recently, Folkman's lab isolated two new factors, called angiostatin and
      endostatin, which are the most powerful growth inhibitors by far. They also
      hold out the promise of an entirely new means of battling cancer. Unlike
      chemotherapy, which can make patients quite ill at high doses, the new
      factors produce only the mildest of side effects. Indeed, standard
      chemotherapy makes cancer-ridden mice listless and easy to catch for their
      daily injections. Those treated with angiostatin and endostatin feel frisky
      enough to put up a fight. "And I've got the bite marks to prove it," says
      Dr. Michael O'Reilly, the postdoctoral fellow who discovered the new
      factors. Drugs based on the new factors also are more likely to keep on
      working: Cancer cells easily develop resistance to chemotherapy; blood
      vessel cells, which reproduce more slowly, are more apt to remain
      susceptible to drugs.

      For all their promise, these newest angiogenesis inhibitors will not be
      widely available for human cancer patients anytime soon. For one thing,
      they are hard to come by. O'Reilly had to collect nearly 3 gallons of mouse
      urine to purify enough angiostatin to treat a dozen mice. And even when
      pharmaceutical companies figure out how to make large quantities of the
      compounds, the drugs must still be tested in human patients, who may not
      respond as well as mice.

      None of which can blunt Folkman's excitement. "I've been waiting for
      results like these my whole life," he says. Last month, Folkman reported
      that a combination of angiostatin and endostatin eradicated lung tumors in
      mice for more than five months--the equivalent of 10 years in a human. "The
      importance of angiogenesis is so obvious when you think about it," says
      Isaiah Fidler of the M. D. Anderson Cancer Center in Houston. "The world
      owes Judah Folkman a debt of gratitude."

      BY SHANNON BROWNLEE

      ------8<---8<---
      (really dated but has terrific, fascinating history, note the reference to
      AIDS
      (Kaposi's sarcoma) and Diabetes(Retinopathies), so angiogenesis factors are
      in Cancer, Heart Disease, and blindness. Folkman is the 'FATHER OF
      ANGIOGENESIS,' so could the Nobel Prize be a long shot? NOPE! This is they
      type of thing my Dad would call a 'no brainer.' )

      http://zygote.swarthmore.edu/mesend3b.html

      ANGIOGENESIS FACTORS IN CANCER, AIDS , AND DIABETES

      Judah Folkman (1974) has estimated that as many as 350 billion mitoses
      occur in each human every day. With each cell division comes the potential
      that the resulting cells will be malignant. Yet very few tumors actually do
      develop in any individual. Folkman has suggested that cells capable of
      forming tumors develop at a certain frequency but that a large majority are
      never able to form observable tumors. The reason is that solid tumor, like
      any other rapidly dividing tissue, needs oxygen and nutrients to survive.
      Without a blood supply, potential tumors either die or remain dormant. Such
      "microtumors" remain as a stable cell population wherein dying cells are
      replaced by new cells.

      The critical point at which this node of tumorous cells becomes a rapidly
      growing tumor occurs when the pocket of cells becomes vascularized. The
      microtumor can expand to 16,000 times its original volume in 2 weeks after
      vascularization. Without the blood supply, no growth is seen (Folkman,
      1974; Ausprunk and Folkman, 1977). To accomplish this vascularization, the
      original microtumor elaborates substances called tumor angiogenesis factors
      (TAF). One such TAF, called angiogenin, has been isolated from a human
      tumor cell population and has been shown to be a single chain protein of
      around 14.4 kDa (Fett et al., 1985). Some tumors, such as many gliomas,
      secrete the VEGF that normally is produced by kidneys and brain cells
      (Plate et al., 1992; Shweiki et al., 1992), and the inhibition of VEGF
      induced angiogenesis suppresses tumor growth in mice (Kim et al., 1993).
      When host endothelial cells are infected with a virus producing a dominant
      negative form of the VEGF receptor, the mice become resistant to
      VEGF-secreting glioblastomas (Millauer et al., 1994).

      TAFs stimulate mitosis in endothelial cells and direct the cells' formation
      into blood vessels in the direction of the tumor. This phenomenon can be
      demonstrated by implanting a piece of tumor tissue within the layers of a
      rabbit or mouse cornea. The cornea itself is not vascularized, but it is
      surrounded by a vascular border, or limbus. Tumor tissue induces blood
      vessels to form and come toward the tumor (Figure 1; Muthukkaruppan et al.,
      1979). Most other adult tissues will not induce these vessels to form. (The
      exceptions are antigen stimulated lymphocytes and macrophages, which
      secrete angiogenesis factors that are probably involved in wound repair.)
      As little as 3.5 pmol of purified angiogenin can induce extensive capillary
      formation in the rabbit cornea. Once the blood vessels enter the tumor, the
      tumor cells undergo explosive growth, eventually bursting the eye.

      FIGURE 1. New blood vessel growth to the site of a tumor in the cornea of
      an albino mouse. (A) Sequence of events leading to the vascularization of a
      mammary adenocarcinoma tumor on days 2, 6, 8, and 12. The veins and
      arteries of the limbus surrounding the cornea both provide vessels. (B)
      Photograph of living cornea of an albino mouse, with new vessels being
      constructed to enter the tumor graft. (A from Muthukkaruppan and Auerbach,
      1979; B courtesy of R. Auerbach.)

      Angiogenesis inhibitors: Possible treatments for cancer Folkman and co
      workers (1983) have shown that certain natural substances inhibit tumor
      induced angiogenesis. Heparin, a complex polysaccharide found in the
      matrices of numerous connective tissues, is a potent inhibitor of
      angiogenesis, especially if administered in the presence of the steroid
      hormone cortisone. When mice with established tumors received injections of
      heparin and cortisone, their tumors markedly regressed. The same
      combination of heparin and cortisone also inhibited normal embryonic
      angiogenesis in chick embryos. A naturally occurring angiogenesis inhibitor
      is also produced by cartilage. This 27,600 Da protein keeps cartilage
      avascular (hence its white, rather than pink, appearance) and is able to
      inhibit angiogenesis in vivo (Moses et al., 1990). Another angiogenesis
      inhibitor, angiostatin, was found to be made by the primary tumors,
      themselves. This protein can act in both paracrine and endocrine fashions.
      It is thought that the presence of this factor actually suppresses the
      growth of smaller metastases. When the primary tumor is removed, these
      secondary, metastatic, growths can then proliferate. Angiostatin turns out
      to be the plasminogen protein with its N-terminal third chopped off. It can
      block angiogenesis and metastases growth when administered to mice
      (O'Reilly et al., 1994). Systemic therapy of mice with angiostatin shows
      that this compound can keep metastatic tumors dormant and can inhibit the
      growth of at least three types of human primary tumors in mice (O'Reilly et
      al., 1996). A third anti-angiogenesis factor, endostatin, has recently been
      isolated. This factor is also made by tumor cells and is the 20 kDa
      C-terminal fragment of collagen XVIII. This compound can stop tumors and
      cause their regression (O'Reilly et al., 1997). Other naturally occuring
      anti-angiogenesis factors include interferons alpha and beta, thrombospondin.

      In recent experiments, Boehm and colleagues (1997) show that
      anti-angiogenic drugs may be extremely useful in combatting tumors. Many
      cancers are able to kill people because the tumor cells are genetically
      unstable and can develop resistance to the drugs used against them.
      Endothelial cells, however, are more stable targets. Boehm and colleagues
      administered endostatin to mice that bore one of three types of tumors.
      They then stopped the treatment when the tumors regressed but had not yet
      been fully eliminated. When the tumor regrew, endostatin therapy was
      resumed. The tumor regressed. The ability of endostatin to cause tumor
      regression was undiminished even after multiple cycles of growth and
      regression. In fact, after several cycles, the tumors remained dormant
      longer. Therefore, anti-angiogenic drugs such as endostatin may be useful
      in long-term maintenance therapy.

      Another approach to blocking tumor-induced angiogenesis involves antibodies
      against integrin proteins. In a series of experiments wherein human tumors
      placed on chick chorioallantoic membranes induced vessels from the CAM to
      enter into the tumor, Brooks and colleagues (1994) showed that the
      maintainance of these new vessels depended on their being bound to the
      substrate by avb3 integrin. Antibodies against this integrin disrupted its
      function and caused the apoptosis of the new blood vessels. The previously
      established blood vessels remained unaffected by the antibodies.

      Hanahan and Folkman (1996) have hypothesized that tumor angiogenesis is
      mediated by a change in the balance between angiogenesis factors (such as
      FGF1, FGF2, and VEGF) and angiogenic inhibitors (such as thrombospondin-1,
      interferons, platelet factor-4, endostatin, and angiostatin). Observations
      on human tumor progression and gene knockout mutations in mice suggest that
      tumor angiogenesis may occur either by a decrease in the amount of
      inhibitor or an increase in the production of angiogenesis factors. The
      signal for new VEGF synthesis in tumor cells might even be the hypoxia the
      cells experience in the center of a pre-malignant cell mass.

      Angiogenesis and metastasis In addition to supplying the tumor with
      nutrients and oxygen, the new blood vessels also provide a route that
      enables tumor cells to migrate to new places, thereby forming secondary
      tumors. This process is called metastasis. Indeed, most victims of cancer
      do not die from the original tumor but from the numerous secondary tumors
      spread by metastasis. To enter a blood vessel, a tumor cell has to lyse the
      collagenous matrix surrounding the new capillaries. This is thought to be
      done by the secretion of a proteolytic enzyme called plasminogen activator.
      This enzyme is important in the implantation of the blastocyst into the
      uterus (Gilbert, 1997, Chapter 5). Tumor cells use this same enzyme to lyse
      a hole in the extracellular matrix surrounding the blood vessels. The
      synthesis of plasminogen activator has been correlated with the metastatic
      ability of tumors, and antibodies to this enzyme have been found to inhibit
      human tumor metastasis (Ossowski and Reich, 1983). Once on the capillary
      endothelial cells, the metastatic tumor cell can squeeze between them and
      enter the bloodstream (Kramer and Nicolson, 1979). Figure 2 shows a
      metastatic melanoma cell squeezing its way between capillary endothelial
      cells.

      FIGURE 2. (A) Attachment, (B) invasion, and (C) migration of a melanoma
      tumor cell (T) under a vascular endothelial cell (e). The melanoma cells
      were placed on the endothelial cells in culture, and photographs were taken
      at intervals of 0.5, 1, and 3 hours. (From Kramer and Nicolson, 1979,
      courtesy of G. Nicolson.)

      Metastasis requires the ability to travel from one site to another. Like
      embryonic cells, many tumor cells need a surface upon which to migrate, and
      some of these cells travel along the extracellular matrix of the blood
      vessel endothelial cells (Nicolson et al., 1981). This migration, like that
      of many embryonic cells, appears to be mediated by components of the
      extracellular basal lamina. When mice are injected with a certain strain of
      melanoma tumor cells, the cells migrate specifically to the lung, where
      they form secondary tumors (Figure 3). When the cells are inhibited from
      binding fibronectin or laminin, over 90 percent of the cells fail to reach
      the lungs (Humphries et al., 1986).



      FIGURE 3. Metastasis of melanoma cells. The ability of particular melanoma
      cells to metastasize to the lung is inhibited by the cell binding regions
      of fibronectin and laminin. Melanoma cells were injected into the tail vein
      of mice. Fourteen days later, the animals were killed with ether and the
      lung metastases were counted. Each point is the average of eight mice.
      (From Humphries et al., 1986, courtesy of K. M. Yamada.)

      In their rapid division and their secretion of plasminogen activator and
      angiogenesis factor and in their migration patterns, tumor cells act like
      normal embryonic cells. There are numerous cases in which tumor cells
      represent adult cells that have reverted to an embryonic stage of their
      existence. This finding suggests new approaches to cancer therapy,
      including the administration of agents that prevent angiogenesis or that
      actually promote the "differentiation" of the "embryonic" tumor cell back
      into a normal, "adult" cell (Sachs, 1978; Jimenez and Yunis, 1987).

      Retinopathies and Kaposi's sarcoma

      One of the symptoms of AIDS is Kaposi's sarcoma, a tumor of blood vessels.
      Usually, this type of tumor is ony found in elderly men of Mediterranean
      ancestry, and it is normally a slow growing and nonlethal cancer. In
      patients with AIDS, this cancer is fast-growing and is seen in young
      adults. Ensoli and colleagues (1994) in Robert Gallo's laboratory have
      shown that vasculogenesis factor FGF2 synergises with the TAT angiogenesis
      inducer of HIV. In "classical" Kaposi's sarcoma, only FGF2 is inducing the
      growth of blood vessels. In the Kaposi's sarcoma of AIDS, both factors are
      at work.

      Another disease characterized by excessive blood vessel growth is diabetic
      retinopathy. About 60,000 diabetic persons each year suffer some degree of
      retinal damage that can lead to blindness. Recent evidence (summarized in
      Barinaga, 1995) suggests that this overproduction of blood vessels is due
      to VEGF. The retina is the most metabolically active tissue in the body,
      and it has an enormous demand for oxygen. In diabetes, it is thought that
      the capillaries supplying blood to the retina get clogged. When this
      happens, oxygen deprivation results. The new studies suggest that this
      oxygen deprivaton stimulates the retina to produce VEGF in an attempt to
      produce more capillaries. However, the vessels do not grow with the proper
      archetecture, nor do they form in an ordered manner. VEGF was found in the
      retina whenever there was oxygen deprivation. This implies that VEGF may
      also be responsible for the retinopathy found in premature infants. When
      babies are born before the blood vessels that supply the retina have been
      completed, the retina lacks the oxygen it needs. About 10,000 premature
      infants each year have proliferative vascular retinopathy wherein abnormal
      blood vessels cross the retina, sometimes destroying vision. If this
      abnormal development could be stopped or redirected, it might be possible
      to prevent the blindess that often results from these proliferative
      conditions.

      References:

      Ausprunk, D. H. and Folkman, J. 1977. Migration and proliferation of
      endothelial cells in preformed and newly formed blood vessels during tumor
      angiogenesis. Microvasc. Res. 14: 53 65.

      Barinaga, M. 1995. Shedding light on blindness. Science 267: 452 - 453.

      Boehm, T., Folkman, J., Browder, T., and O'Reilly, M. S. 1997.
      Antiangiogenic therapy of experimental cancer does not induce acquired drug
      resistance. Nature 390: 404 - 407.

      Brooks, P. C. Montgomery, A. M. P., Rosenfeld, M., Reisfeld, R. A., Hu, T.,
      Klier, G., and Cheresh, D. A. 1994. Human avb3 antagonists promote tumor
      regression by inducing apoptosis of angiogenic blood vessels. Cell 79: 1157
      - 1164.

      Ensoli, B. and several others. 1994. Synergy between basic fibroblast
      growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma.
      Nature 371: 674 - 678.

      Fett, J. W., Strydom, D. J., Lubb, R. R., Alderman, E. M., Bethune, J. L.,
      Riordan, J. F. and Vallee, B. L. 1985. Isolation and characterization of
      angiogenin, an angiogenic protein from human carcinoma cells. Biochemistry
      24: 5480 5486.

      Folkman, J. 1974. Tumor angiogenesis. Adv. Cancer Res. 19: 331 358.

      Folkman, J., Langer, R., Linhardt, R. J., Haudenschild, C. and Taylor, S.
      1983. Angiogenesis inhibition and tumor regression caused by heparin or
      heparin fragment in the presence of cortisone. Science 221: 719 725.

      Hanahan, D. and Folkman, J. 1996. Patterns and emerging mechanisms of the
      angiogenic switch during tumorigenesis. Cell 86: 353 - 364.

      Humphries, M. J., Oldern, K. and Yamada, K. M. 1986. A synthetic peptide
      from fibronectin inhibits experimental metastasis in murine melanoma cells.
      Science 233: 467 470.

      Jimenez, J. J. and Yunis, A. A. 1987. Tumor cell rejection through terminal
      cell differentiation. Science 238: 1278 1280.

      Kim, K. J. and seven others. 1993. Inhibition of vascular endothelial
      growth factor induced angiogenesis suppresses tumour growth in vivo.
      Nature362: 841 844.

      Kramer, R. H. and Nicolson, G. L. 1979. Interaction of tumor cells with
      vascular endothelial cell monolayers: A model for metastatic invasion.
      Proc. Natl. Acad. Sci. USA 76: 5704 5708.

      Millauer, B., Shawyer, L. K., Plate, K. H., Risau, W., and Ullrich, A.
      1994. Glioblastoma growth inhibited in vivo by a dominant negative Flk-1
      mutant. Nature 367: 576 - 579.

      Moses, M. A., Sudhalter, J. and Langer, R. 1990. Identification of an
      inhibitor of neovascularization from cartilage. Science 248: 1408 1410.

      Muthukkaruppan, V. R. and Auerbach, R. 1979. Angiogenesis in the mouse
      cornea. Science 205: 1416 1418.

      Nicolson, G. L., Irimura, T., Gonzalez, R. and Ruoslahti, E. 1981. The role
      of fibronectin in adhesion of metastatic melanoma cells to endothelial
      cells and their basal lamina. Exp. Cell Res. 135: 461 465.

      O'Reilly, M. S. and several others. 1994. Angiostatin: A novel angiogenesis
      inhibitor that mediates the suppression of metastases by a Lewis lung
      carcinoma. Cell 79: 315 - 328.

      O'Reilly, M. S., Holmgren, L., Chen, C. C., and Folkman, J. 1996.
      Angiostatin induces and sustains dormancy of human primary tumors in mice.
      Med. Genet. 2: 689 - 692.

      O'Reilly, M. S. and nine others. 1997. Endostatin: an endogenous inhibitor
      of angiogenesis and tumor growth. Cell 88: 277 - 285.

      Ossowski, L. and Reich, E. 1983. Antibodies to plasminogen activator
      inhibit tumor metastasis. Cell 35: 611 619.

      Plate, K. H., Breier, G., Weich, H. A. and Risau, W. 1992. Vascular
      endothelial growth factor is a potential tumour angiogenesis factor in
      human gliomas in vivo. Nature 359: 845 848.

      Sachs, L. 1978. Control of normal cell differentiation and the phenotypic
      reversion of malignancy in myeloid leukemias. Nature 274: 535 539.

      Shweiki, D., Itin, A., Soffer, D. and Keshet, E. 1992. Vascular endothelial
      growth factor induced by hypoxia may mediate hypoxia initiated
      angiogenesis. Nature 359: 843 845.

      ---8<---8<--
      Another site that I haven't checked out but want to:

      http://headlines.yahoo.com/Full_Coverage/Tech/Cancer_Research/